Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients with Bipolar Depression

Exclusion Criteria

• - Patients with a current Diagnostic and Statistical Manual of Mental Disorders - 4th Edition (DSM-IV) diagnosis other than bipolar disorder
• - Patients whose Young Mania Rating Scale (YMRS) total score >12 at enrolment and randomisation.
• - Patients with >8 mood episodes during the past 12 months at enrolment.
• - Patients whose current episode of depression exceeds 12 months or is less than 4 weeks from enrolment.
• - Patients with a history of non-response to an adequate treatment (6 weeks) with
• more than 2 classes of antidepressants during their current episode.
• - Alcohol or other substance dependence or abuse as defined by Diagnostic and Statistical Manual of Mental Disorders - 4th Edition (DSM-IV) criteria at enrolment that is not in extended full or extended partial remission (12 months or longer), except caffeine and nicotine dependence.
• - Patients who, in the Investigator's judgment, pose a current serious suicidal or
• homicidal risk, have a Hamilton Rating Scale for Depression (HAM-D) item 3 score ≥ 3, or have made a suicide attempt within the past 6 months.